TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Prospective, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate Smoking Cessation With Varenicline Tartrate Compared With Placebo In The Setting Of Patient Self-Selected (Flexible) Quit Date
Brief Summary: The hypothesis is that varenicline will be effective (compared with placebo) for smoking cessation when subjects are allowed to set their own quit date within the first 5 weeks of treatment.


Options:
A: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline
D: Arm Label: Extended Brief Contact; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Check-ins with medical staff | Arm Label: Extended Health Education; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Extended Individual Counseling - Health Model | Arm Label: Extended Relapse Prevention plus varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Extended Individual Counseling - Relapse Prevention Model | Arm Label: Extended Relapse Prevention; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Extended Individual Counseling - Relapse Prevention Model | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Extended Brief Contact, Extended Health Education, Extended Relapse Prevention, Extended Relapse Prevention plus varenicline | Intervention Type: BEHAVIORAL; Name: Initial Individual counseling; Assigned to Arm(s): Extended Brief Contact, Extended Health Education, Extended Relapse Prevention, Extended Relapse Prevention plus varenicline | Intervention Type: BEHAVIORAL; Name: Check-ins with medical staff; Assigned to Arm(s): Extended Brief Contact | Intervention Type: BEHAVIORAL; Name: Extended Individual Counseling - Health Model; Assigned to Arm(s): Extended Health Education | Intervention Type: BEHAVIORAL; Name: Extended Individual Counseling - Relapse Prevention Model; Assigned to Arm(s): Extended Relapse Prevention, Extended Relapse Prevention plus varenicline

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Prospective, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate Smoking Cessation With Varenicline Tartrate Compared With Placebo In The Setting Of Patient Self-Selected (Flexible) Quit Date
Brief Summary: The hypothesis is that varenicline will be effective (compared with placebo) for smoking cessation when subjects are allowed to set their own quit date within the first 5 weeks of treatment.


Options:
A: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Prospective, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate Smoking Cessation With Varenicline Tartrate Compared With Placebo In The Setting Of Patient Self-Selected (Flexible) Quit Date
Brief Summary: The hypothesis is that varenicline will be effective (compared with placebo) for smoking cessation when subjects are allowed to set their own quit date within the first 5 weeks of treatment.


Options:
A: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Intervention | Intervention Type: OTHER; Name: Intervention; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Arm Label: Varenicline + Active Patch; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Drug: Varenicline | Arm Label: Varenicline + Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Varenicline + Active Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Patch, Varenicline + Placebo Patch
C: Arm Label: Varenicline + Active Tailored Dose; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline + Placebo Tailored Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Tailored Dose | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose, Varenicline + Placebo Tailored Dose
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Prospective, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate Smoking Cessation With Varenicline Tartrate Compared With Placebo In The Setting Of Patient Self-Selected (Flexible) Quit Date
Brief Summary: The hypothesis is that varenicline will be effective (compared with placebo) for smoking cessation when subjects are allowed to set their own quit date within the first 5 weeks of treatment.


Options:
A: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Varenicline & nicotine patches; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Nicotine patches | Arm Label: Varenicline & placebo patches; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo (nicotine patches) | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline & nicotine patches, Varenicline & placebo patches | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Varenicline & nicotine patches | Intervention Type: DRUG; Name: Placebo (nicotine patches); Assigned to Arm(s): Varenicline & placebo patches
C: Arm Label: varenicline and buproprion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: bupropion SR | Arm Label: varenicline and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline and buproprion SR, varenicline and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): varenicline and placebo | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): varenicline and buproprion SR
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Prospective, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate Smoking Cessation With Varenicline Tartrate Compared With Placebo In The Setting Of Patient Self-Selected (Flexible) Quit Date
Brief Summary: The hypothesis is that varenicline will be effective (compared with placebo) for smoking cessation when subjects are allowed to set their own quit date within the first 5 weeks of treatment.


Options:
A: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Bupropion | Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1
B: Arm Label: Selegiline Transdermal Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Selegiline Transdermal Patch, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Selegiline Transdermal Patch; Assigned to Arm(s): Selegiline Transdermal Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Placebo, Selegiline Transdermal Patch
C: Arm Label: Arm I (varenicline); Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II (nicotine patch); Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I (varenicline) | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): Arm II (nicotine patch)
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Prospective, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate Smoking Cessation With Varenicline Tartrate Compared With Placebo In The Setting Of Patient Self-Selected (Flexible) Quit Date
Brief Summary: The hypothesis is that varenicline will be effective (compared with placebo) for smoking cessation when subjects are allowed to set their own quit date within the first 5 weeks of treatment.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline
B: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Nicotine Patches only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches | Arm Label: Nicotine Patches with Nicotine Inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, Drug: Nicotine Inhaler | Arm Label: varenicline with bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline, varenicline with bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): varenicline with bupropion | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Nicotine Patches only, Nicotine Patches with Nicotine Inhaler | Intervention Type: DRUG; Name: Nicotine Inhaler; Assigned to Arm(s): Nicotine Patches with Nicotine Inhaler

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Prospective, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate Smoking Cessation With Varenicline Tartrate Compared With Placebo In The Setting Of Patient Self-Selected (Flexible) Quit Date
Brief Summary: The hypothesis is that varenicline will be effective (compared with placebo) for smoking cessation when subjects are allowed to set their own quit date within the first 5 weeks of treatment.


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Matched Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo for varenicline; Assigned to Arm(s): Matched Placebo
B: Arm Label: QA-DDS; Type: EXPERIMENTAL; Interventions: Behavioral: QA-DDS | Intervention Type: BEHAVIORAL; Name: QA-DDS; Assigned to Arm(s): QA-DDS
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Extended IVR (integrated voice response technology), Drug: Varenicline (Champix), Behavioral: IVR treatment | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline (Champix), Behavioral: IVR treatment | Intervention Type: BEHAVIORAL; Name: Extended IVR (integrated voice response technology); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Varenicline (Champix); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: IVR treatment; Assigned to Arm(s): 1, 2
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Prospective, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate Smoking Cessation With Varenicline Tartrate Compared With Placebo In The Setting Of Patient Self-Selected (Flexible) Quit Date
Brief Summary: The hypothesis is that varenicline will be effective (compared with placebo) for smoking cessation when subjects are allowed to set their own quit date within the first 5 weeks of treatment.


Options:
A: Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline tartrate | Arm Label: bupropion; Type: EXPERIMENTAL; Interventions: Drug: bupropion hydrochloride | Arm Label: Nicotine Replacement Therapy Patch; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Replacement Therapy Patch | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline tartrate; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: bupropion hydrochloride; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: Nicotine Replacement Therapy Patch; Assigned to Arm(s): Nicotine Replacement Therapy Patch
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline
C: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Varenicline and Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline and Placebo Patch | Arm Label: Varenicline and Nicotine Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Nicotine Patch | Intervention Type: DRUG; Name: Varenicline, Nicotine Patch; Assigned to Arm(s): Varenicline and Nicotine Patch | Intervention Type: DRUG; Name: Varenicline and Placebo Patch; Assigned to Arm(s): Varenicline and Placebo Patch

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Brief Summary: Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis


Options:
A: Arm Label: 80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: 80 mg Ixekizumab Dosing Regimen 2 (Q4W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: 80 mg Ixekizumab Dosing Regimen 3 (Q12W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3; Assigned to Arm(s): 80 mg Ixekizumab Dosing Regimen 2 (Q4W), 80 mg Ixekizumab Dosing Regimen 3 (Q12W), 80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: ABT-874 | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Biological: etanercept | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: BIOLOGICAL; Name: ABT-874; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 140 mg SC; Type: EXPERIMENTAL; Interventions: Drug: 140 mg SC | Arm Label: 350 mg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: 350 mg SC | Arm Label: 700 mg IV; Type: EXPERIMENTAL; Interventions: Drug: 700 mg IV | Intervention Type: DRUG; Name: 700 mg IV; Assigned to Arm(s): 700 mg IV | Intervention Type: DRUG; Name: 350 mg SC; Assigned to Arm(s): 350 mg SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 140 mg SC; Assigned to Arm(s): 140 mg SC
D: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: ActiveTreatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): ActiveTreatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Brief Summary: Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti IL-12 monoclonal antibody/ABT-874 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti IL-12 monoclonal antibody/ABT-874 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti IL-12 monoclonal antibody/ABT-874 | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti IL-12 monoclonal antibody/ABT-874 | Arm Label: 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti IL-12 monoclonal antibody/ABT-874 | Arm Label: 6; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Anti IL-12 monoclonal antibody/ABT-874; Assigned to Arm(s): 1, 2, 3, 4, 5 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 6
B: Arm Label: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 200 mg, Drug: Matching Placebo | Arm Label: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 100 mg, Drug: Matching Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tildrakizumab 200 mg, Drug: Tildrakizumab 100 mg, Drug: Matching Placebo | Intervention Type: DRUG; Name: Tildrakizumab 200 mg; Assigned to Arm(s): Placebo, Tildrakizumab 200 mg | Intervention Type: DRUG; Name: Tildrakizumab 100 mg; Assigned to Arm(s): Placebo, Tildrakizumab 100 mg | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): Placebo, Tildrakizumab 100 mg, Tildrakizumab 200 mg
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: ABT-874 | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Biological: etanercept | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: BIOLOGICAL; Name: ABT-874; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C
D: Arm Label: adalimumab + placebo; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: placebo (vehicle ointment) | Arm Label: adalimumab + calcipotriol/betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: Calcipotriol/Betamethasone Ointment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone, adalimumab + placebo | Intervention Type: DRUG; Name: Calcipotriol/Betamethasone Ointment; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone | Intervention Type: DRUG; Name: placebo (vehicle ointment); Assigned to Arm(s): adalimumab + placebo

Answer: C